Literature DB >> 1644864

SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells.

P Hasselaar1, E H Sage.   

Abstract

Migration of endothelial cells is requisite to wound repair and angiogenesis. Since the glycoprotein SPARC (secreted protein, acidic and rich in cysteine) is associated with remodeling, cellular migration, and angiogenesis in vitro, we questioned whether SPARC might influence the motility of endothelial cells. In this study we show that, in the absence of serum, exogenous SPARC inhibits the migration of bovine aortic endothelial cells induced by bFGF. Similar results were obtained from two different assays, in which cell migration was measured in a Boyden chamber and in monolayer culture after an experimental wound. Without bFGF, the migration of endothelial cells was unaffected by SPARC. The inhibitory effect of SPARC on cell motility was dose-dependent, required the presence of Ca2+, was mimicked by synthetic peptides from the N- and C-terminal Ca(2+)-binding domains of the protein, and was not seen in the presence of serum. Modulation of the activities of secreted and cell-associated proteases, including plasminogen activators and metalloproteinases, appeared not to be responsible for the effects that we observed on the motility of endothelial cells. Moreover, a molecular interaction between SPARC and bFGF was not detected, and SPARC did not interfere with the binding of bFGF to high-affinity receptors on endothelial cells. Finally, in culture medium that contained serum, SPARC inhibited the incorporation of [3H]-thymidine into newly synthesized DNA, both in the absence and presence of bFGF. However, DNA synthesis was not affected by SPARC when the cells were plated on gelatin or fibronectin in serum-free medium. We propose that the combined action of a serum factor and SPARC regulates both endothelial cell proliferation and migration and coordinates these events during morphogenetic processes such as wound repair and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1644864     DOI: 10.1002/jcb.240490310

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  35 in total

1.  SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system.

Authors:  Barbara J Schiemann; Jason R Neil; William P Schiemann
Journal:  Mol Biol Cell       Date:  2003-06-27       Impact factor: 4.138

2.  Osteonectin (SPARC) expression in human liver and in cultured human liver myofibroblasts.

Authors:  S Blazejewski; B Le Bail; L Boussarie; J F Blanc; L Malaval; K Okubo; J Saric; P Bioulac-Sage; J Rosenbaum
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

Review 3.  The counteradhesive proteins, thrombospondin 1 and SPARC/osteonectin, open the tyrosine phosphorylation-responsive paracellular pathway in pulmonary vascular endothelia.

Authors:  Anguo Liu; Deane F Mosher; Joanne E Murphy-Ullrich; Simeon E Goldblum
Journal:  Microvasc Res       Date:  2008-10-01       Impact factor: 3.514

4.  Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma.

Authors:  Shanna A Arnold; Lee B Rivera; Andrew F Miller; Juliet G Carbon; Sean P Dineen; Yang Xie; Diego H Castrillon; E Helene Sage; Pauli Puolakkainen; Amy D Bradshaw; Rolf A Brekken
Journal:  Dis Model Mech       Date:  2009-12-09       Impact factor: 5.758

5.  Secreted Protein Acidic and Rich in Cysteine Modulates Molecular Arterial Homeostasis of Human Arterial Smooth Muscle Cells In Vitro.

Authors:  Geng-Fan Ye; Shao-Wei Zhu; Shu-Gan Zhu; Feng Li; Yun-Yan Wang
Journal:  J Mol Neurosci       Date:  2016-08-25       Impact factor: 3.444

6.  SPARC/osteonectin mRNA is induced in blood vessels following injury to the adult rat cerebral cortex.

Authors:  D B Mendis; G O Ivy; I R Brown
Journal:  Neurochem Res       Date:  1998-08       Impact factor: 3.996

7.  SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-medicated mesangial cell proliferation in vitro.

Authors:  R H Pichler; J A Bassuk; C Hugo; M J Reed; E Eng; K L Gordon; J Pippin; C E Alpers; W G Couser; E H Sage; R J Johnson
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

8.  Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer.

Authors:  Jian-fang Liang; Hong-kun Wang; Hong Xiao; Ning Li; Cai-xia Cheng; Yu-ze Zhao; Yan-b Ma; Jian-zhong Gao; Rui-bing Bai; Hui-xia Zheng
Journal:  J Exp Clin Cancer Res       Date:  2010-06-16

9.  Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.

Authors:  Alexandre Chlenski; Lisa J Guerrero; Radhika Peddinti; Jared A Spitz; Payton T Leonhardt; Qiwei Yang; Yufeng Tian; Helen R Salwen; Susan L Cohn
Journal:  Mol Cancer       Date:  2010-06-04       Impact factor: 27.401

10.  The role of MMP-9 in the anti-angiogenic effect of secreted protein acidic and rich in cysteine.

Authors:  P Bhoopathi; C Chetty; M Gujrati; D H Dinh; J S Rao; S S Lakka
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.